rs2498796

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_001382430.1(AKT1):​c.176-113C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.335 in 808,566 control chromosomes in the GnomAD database, including 48,295 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.34 ( 9143 hom., cov: 33)
Exomes 𝑓: 0.33 ( 39152 hom. )

Consequence

AKT1
NM_001382430.1 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: -0.249

Publications

17 publications found
Variant links:
Genes affected
AKT1 (HGNC:391): (AKT serine/threonine kinase 1) This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
AKT1 Gene-Disease associations (from GenCC):
  • Proteus syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cowden syndrome 6
    Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant 14-104776883-G-A is Benign according to our data. Variant chr14-104776883-G-A is described in ClinVar as Benign. ClinVar VariationId is 1264628.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.593 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
AKT1NM_001382430.1 linkc.176-113C>T intron_variant Intron 4 of 14 ENST00000649815.2 NP_001369359.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
AKT1ENST00000649815.2 linkc.176-113C>T intron_variant Intron 4 of 14 NM_001382430.1 ENSP00000497822.1 P31749-1

Frequencies

GnomAD3 genomes
AF:
0.339
AC:
51457
AN:
151954
Hom.:
9147
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.320
Gnomad AMI
AF:
0.289
Gnomad AMR
AF:
0.429
Gnomad ASJ
AF:
0.288
Gnomad EAS
AF:
0.611
Gnomad SAS
AF:
0.491
Gnomad FIN
AF:
0.334
Gnomad MID
AF:
0.326
Gnomad NFE
AF:
0.303
Gnomad OTH
AF:
0.327
GnomAD4 exome
AF:
0.334
AC:
219287
AN:
656494
Hom.:
39152
Cov.:
9
AF XY:
0.339
AC XY:
115106
AN XY:
339944
show subpopulations
African (AFR)
AF:
0.318
AC:
5345
AN:
16802
American (AMR)
AF:
0.476
AC:
12266
AN:
25766
Ashkenazi Jewish (ASJ)
AF:
0.282
AC:
4560
AN:
16190
East Asian (EAS)
AF:
0.566
AC:
17768
AN:
31402
South Asian (SAS)
AF:
0.449
AC:
24745
AN:
55068
European-Finnish (FIN)
AF:
0.339
AC:
10691
AN:
31572
Middle Eastern (MID)
AF:
0.346
AC:
963
AN:
2782
European-Non Finnish (NFE)
AF:
0.297
AC:
131960
AN:
444100
Other (OTH)
AF:
0.335
AC:
10989
AN:
32812
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
6768
13535
20303
27070
33838
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2700
5400
8100
10800
13500
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.339
AC:
51482
AN:
152072
Hom.:
9143
Cov.:
33
AF XY:
0.344
AC XY:
25604
AN XY:
74350
show subpopulations
African (AFR)
AF:
0.320
AC:
13257
AN:
41452
American (AMR)
AF:
0.429
AC:
6560
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.288
AC:
999
AN:
3470
East Asian (EAS)
AF:
0.610
AC:
3155
AN:
5168
South Asian (SAS)
AF:
0.490
AC:
2367
AN:
4826
European-Finnish (FIN)
AF:
0.334
AC:
3540
AN:
10592
Middle Eastern (MID)
AF:
0.313
AC:
92
AN:
294
European-Non Finnish (NFE)
AF:
0.302
AC:
20552
AN:
67950
Other (OTH)
AF:
0.330
AC:
697
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
1737
3473
5210
6946
8683
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
516
1032
1548
2064
2580
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.321
Hom.:
981
Bravo
AF:
0.344
Asia WGS
AF:
0.530
AC:
1842
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jan 10, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.88
CADD
Benign
1.3
DANN
Benign
0.44
PhyloP100
-0.25
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
3.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2498796; hg19: chr14-105243220; COSMIC: COSV62573593; COSMIC: COSV62573593; API